F
Florian Klein
Researcher at University of Cologne
Publications - 128
Citations - 7531
Florian Klein is an academic researcher from University of Cologne. The author has contributed to research in topics: Antibody & B cell. The author has an hindex of 36, co-authored 124 publications receiving 4798 citations. Previous affiliations of Florian Klein include Rockefeller University & University of Bonn.
Papers
More filters
Journal ArticleDOI
Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys
Dan H. Barouch,James B. Whitney,Brian Moldt,Florian Klein,Thiago Y. Oliveira,Jinyan Liu,Kathryn E. Stephenson,Hui-Wen Chang,Karthik Shekhar,Sanjana Gupta,Joseph P. Nkolola,Michael S. Seaman,Kaitlin M. Smith,Erica N. Borducchi,Crystal Cabral,Jeffrey Y. Smith,Stephen Blackmore,Srisowmya Sanisetty,James R. Perry,Matthew Beck,Mark G. Lewis,William Rinaldi,Arup K. Chakraborty,Arup K. Chakraborty,Pascal Poignard,Michel C. Nussenzweig,Michel C. Nussenzweig,Dennis R. Burton,Dennis R. Burton +28 more
TL;DR: A profound therapeutic effect of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys as well as an impact on host immune responses are demonstrated.
Journal ArticleDOI
COVID-19 associated pulmonary aspergillosis.
Philipp Koehler,Oliver A. Cornely,Bernd W. Böttiger,Fabian Dusse,Dennis A. Eichenauer,Frieder Fuchs,Michael Hallek,Norma Jung,Florian Klein,Thorsten Persigehl,Jan Rybniker,Matthias Kochanek,Boris Böll,Alexander Shimabukuro-Vornhagen +13 more
TL;DR: This study evaluates coronavirus disease 19 (COVID‐19) associated invasive aspergillosis at a single centre in Cologne, Germany to evaluate patients with acute respiratory distress syndrome due to viral infection.
Journal ArticleDOI
Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study.
Max Augustin,Philipp Schommers,Melanie Stecher,Felix Dewald,Lutz Gieselmann,Henning Gruell,Carola Horn,Kanika Vanshylla,Veronica Di Cristanziano,Luise Osebold,Maria Roventa,Toqeer Riaz,Nikolai Tschernoster,Janine Altmueller,Leonard Rose,Susanne Salomon,Vanessa Priesner,Jan Christoffer Luers,Christian Albus,Stephan Rosenkranz,Birgit S. Gathof,Gerd Fätkenheuer,Michael Hallek,Florian Klein,Isabelle Suárez,Clara Lehmann +25 more
TL;DR: The on-going presence of either shortness of breath, anosmia, ageusia or fatigue as long-lasting symptoms even in non-hospitalised patients was observed at four and seven months post-infection and summarised as post-COVID syndrome (PCS).
Journal ArticleDOI
Antibody 10-1074 suppresses viremia in HIV-1-infected individuals
Marina Caskey,Till Schoofs,Henning Gruell,Allison Settler,Theodora K. Karagounis,Edward F. Kreider,Ben Murrell,Nico Pfeifer,Lilian Nogueira,Thiago Y. Oliveira,Gerald H. Learn,Yehuda Z. Cohen,Clara Lehmann,Daniel Gillor,Irina Shimeliovich,Cecilia Unson-O’Brien,Daniela Weiland,Alexander. Robles,Tim Kümmerle,Christoph Wyen,Rebeka Levin,Maggi Witmer-Pack,Kemal Eren,Caroline Ignacio,Szilard Kiss,Anthony P. West,Hugo Mouquet,Barry S. Zingman,Barry S. Zingman,Roy M. Gulick,Tibor Keler,Pamela J. Bjorkman,Michael S. Seaman,Beatrice H. Hahn,Gerd Fätkenheuer,Sarah J. Schlesinger,Michel C. Nussenzweig,Michel C. Nussenzweig,Florian Klein +38 more
TL;DR: The results demonstrate the safety and activity of 10-1074 in humans and support the idea that antibodies targeting the V3 glycan supersite might be useful for the treatment and prevention of HIV-1 infection.
Journal ArticleDOI
Combination therapy with anti-HIV-1 antibodies maintains viral suppression
Pilar Mendoza,Henning Gruell,Lilian Nogueira,Joy A. Pai,Allison L. Butler,Katrina G. Millard,Clara Lehmann,Isabelle Suárez,Thiago Y. Oliveira,Julio C. C. Lorenzi,Yehuda Z. Cohen,Christoph Wyen,Christoph Wyen,Tim Kümmerle,Tim Kümmerle,Theodora K. Karagounis,Ching-Lan Lu,Lisa Handl,Cecilia Unson-O’Brien,Roshni Patel,Carola Ruping,Maike Schlotz,Maggi Witmer-Pack,Irina Shimeliovich,Gisela Kremer,Eleonore Thomas,Kelly E. Seaton,Jill Horowitz,Anthony P. West,Pamela J. Bjorkman,Georgia D. Tomaras,Roy M. Gulick,Nico Pfeifer,Gerd Fätkenheuer,Michael S. Seaman,Florian Klein,Marina Caskey,Michel C. Nussenzweig,Michel C. Nussenzweig +38 more
TL;DR: It is concluded that the combination of the anti-HIV-1 monoclonal antibodies 3BNC117 and 10-1074 can maintain long-term suppression in the absence of antiretroviral therapy in individuals with antibody-sensitive viral reservoirs.